Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma

Journal of Immunotherapy

Volumn 38, Issue 5, 2015, Pages 197-210

  Müller, Nadja ^a   Michen, Susanne ^a   Tietze, Stefanie ^a   Töpfer, Katrin ^a   Schulte, Alexander ^d   Lamszus, Katrin ^d   Schmitz, Marc ^b   Schackert, Gabriele ^a,c   Pastan, Ira ^e   Temme, Achim ^a,c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptor; CXCL12 SDF 1 ; CXCR4; EGFRvIII; Engineered NK cell chemotaxis

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR VARIANT III; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; NATURAL KILLER CELL RECEPTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ENGINEERING; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR GROWTH; TUMOR REGRESSION; ADMINISTRATION AND DOSAGE; ANIMAL; BIOLOGICAL THERAPY; BIOSYNTHESIS; CELL LINE; CHEMOTAXIS; CYTOTOXICITY; DISEASE MODEL; DRUG SCREENING; ECTOPIC EXPRESSION; FEMALE; GENE EXPRESSION; GENE ORDER; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LENTIVIRINAE; METABOLISM; MORTALITY; PATHOLOGY; TUMOR VOLUME;

ANIMALS; CELL LINE; CELL- AND TISSUE-BASED THERAPY; CHEMOKINE CXCL12; CHEMOTAXIS; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; ECTOPIC GENE EXPRESSION; FEMALE; GENE EXPRESSION; GENE ORDER; GENETIC THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LENTIVIRUS; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CXCR4; RECOMBINANT FUSION PROTEINS; TRANSDUCTION, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929677695     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000082     Document Type: Article

References (66)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
2. Topfer K, Kempe S, Muller N, et al. Tumor evasion from T cell surveillance. J Biomed Biotechnol. 2011;2011:918471, 1-19 DOI: 10.1155/2011/918471.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
4. Darcy PK, Neeson P, Yong CS, et al. Manipulating immune cells for adoptive immunotherapy of cancer. Curr Opin Immunol. 2014;27C:46-52.
5. Sampson JH, Choi BD, Sanchez-Perez L, et al. EGFRvIII mCAR-modified T cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2013;20:972-984.
6. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116:1035-1044.
7. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001;1:41-49.
8. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44-49.
9. Paust S, von Andrian UH. Natural killer cell memory. Nat Immunol. 2011;12:500-508.
10. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495-502.
11. Brooks AG, Boyington JC, Sun PD. Natural killer cell recognition of HLA class I molecules. Rev Immunogenet. 2000;2:433-448.
12. Karre K. Express yourself or die: peptides, MHC molecules, and NK cells. Science. 1995;267:978-979.
13. Smyth MJ, Cretney E, Kelly JM, et al. Activation of NK cell cytotoxicity. Mol Immunol. 2005;42:501-510.
14. Oshimi Y, Oda S, Honda Y, et al. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J Immunol. 1996;157:2909-2915.
15. Shrikant P, Mescher MF. Control of syngeneic tumor growth by activation of CD8 + T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol. 1999;162:2858-2866.
16. Rossig C, Bollard CM, Nuchtern JG, et al. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001;94:228-236.
17. Lizee G, Cantu MA, Hwu P. Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res. 2007;13(18 pt 1):5250-5255.
18. Kmiecik J, Zimmer J, Chekenya M. Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J Neurooncol. 2014;116:1-9.
19. Madri JA, Graesser D. Cell migration in the immune system: the evolving inter-related roles of adhesion molecules and proteinases. Dev Immunol. 2000;7:103-116.
20. Charalambous C, Hofman FM, Chen TC. Functional and phenotypic differences between glioblastoma multiforme-derived and normal human brain endothelial cells. J Neurosurg. 2005;102:699-705.
21. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;272:2927-2935.
22. Beers R, Chowdhury P, Bigner D, et al. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res. 2000;6:2835-2843.
23. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem. 2005;280: 35760-35766.
24. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006;203: 2201-2213.
25. Berahovich RD, Zabel BA, Penfold ME, et al. CXCR7 protein is not expressed on human or mouse leukocytes. J Immunol. 2010;185:5130-5139.
26. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA. 1994;91:2305-2309.
27. Mayol K, Biajoux V, Marvel J, et al. Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking. Blood. 2011;118:4863-4871.
28. Luo Y, Lathia J, Mughal M, et al. SDF1alpha/CXCR4 signaling, via ERKs and the transcription factor Egr1, induces expression of a 67-kDa form of glutamic acid decarboxylase in embryonic hippocampal neurons. J Biol Chem. 2008;283: 24789-24800.
29. Jiang Z, Zhou W, Guan S, et al. Contribution of SDF-1alpha/CXCR4 signaling to brain development and glioma progression. Neurosignals. 2013;21:240-258.
30. Sehgal A, Keener C, Boynton AL, et al. CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol. 1998;69: 99-104.
31. Bajetto A, Barbieri F, Dorcaratto A, et al. Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation and migration. Neurochem Int. 2006;49:423-432.
32. Barbero S, Bonavia R, Bajetto A, et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res. 2003;63:1969-1974.
33. Schulte A, Gunther HS, Phillips HS, et al. A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. Glia. 2011;59:590-602.
34. Salmaggi A, Gelati M, Pollo B, et al. CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. J Neurooncol. 2005;74:287-293.
35. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol. 1999;154:1125-1135.
36. Jones G, Machado J Jr, Merlo A. Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells. Cancer Res. 2001;61: 4978-4981.
37. Kuan CT, Wikstrand CJ, Archer G, et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer. 2000;88:962-969.
38. Amer DA, Kretzschmar G, Muller N, et al. Activation of transgenic estrogen receptor-beta by selected phytoestrogens in a stably transduced rat serotonergic cell line. J Steroid Biochem Mol Biol. 2010;120:208-217.
39. Zufferey R, Donello JE, Trono D, et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. 1999;73:2886-2892.
40. Topfer K, Cartellieri M, Michen S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194:3201-3212.
41. Mochizuki H, Schwartz JP, Tanaka K, et al. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol. 1998;72: 8873-8883.
42. Kalajzic I, Stover ML, Liu P, et al. Use of VSV-G pseudotyped retroviral vectors to target murine osteoprogenitor cells. Virology. 2001;284:37-45.
43. Morgenroth A, Cartellieri M, Schmitz M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate. 2007;67: 1121-1131.
44. Temme A, Geiger KD, Wiedemuth R, et al. Giant cell glioblastoma is associated with altered aurora B expression and concomitant p53 mutation. J Neuropathol Exp Neurol. 2010;69:632-642.
45. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA. 1994;91: 7727-7731.
46. Schulte A, Liffers K, Kathagen A, et al. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110delta. Neuro Oncol. 2013;15:1289-1301.
47. Schonfeld K, Sahm C, Zhang C, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23: 330-338. 6.
48. Zlotnik A. Chemokines and cancer. Int J Cancer. 2006;119: 2026-2029.
49. Franciszkiewicz K, Boissonnas A, Boutet M, et al. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res. 2012; 72:6325-6332.
50. Kershaw MH, Wang G, Westwood JA, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther. 2002;13: 1971-1980.
51. Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res. 2011;17:4719-4730.
52. Craddock JA, Lu A, Bear A, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33:780-788.
53. Gumbleton M, Kerr WG. Role of inositol phospholipid signaling in natural killer cell biology. Front Immunol. 2013;4:1-8.
54. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
55. Handel TM, Johnson Z, Crown SE, et al. Regulation of protein function by glycosaminoglycans - as exemplified by chemokines. Annu Rev Biochem. 2005;74:385-410.
56. Radaelli E, Ceruti R, Patton V, et al. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol. 2009;24:879-891.
57. Wang M, Wang T, Liu S, et al. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol. 2003;20:65-72.
58. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001;276:43503-43508.
59. Perry JR. Thromboembolic disease in patients with highgrade glioma. Neuro Oncol. 2012;14(suppl 4):iv73-iv80.
60. Li J, Anderson MG, Tucker LA, et al. Inhibition of aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2. Cell Death Differ. 2009;16:498-511.
61. Hendruschk S, Wiedemuth R, Aigner A, et al. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol. 2011;13: 1074-1089.
62. Codo P, Weller M, Meister G, et al. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget. 2014;5:7651-7662.
63. Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004;64:7954-7961.
64. Naumann U, Maass P, Gleske AK, et al. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. Int J Oncol. 2008;33:759-765.
65. Emlet DR, Gupta P, Holgado-Madruga M, et al. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res. 2014;74:1238-1249.
66. Mangan JK, Luger SM. Salvage therapy for relapsed or refractory acute myeloid leukemia. Ther Adv Hematol. 2011;2:73-82.